Cargando…

Relationships between big‐five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease

INTRODUCTION: Changes in personality characteristics are associated with the onset of symptoms in Alzheimer's disease (AD) and may even precede clinical diagnosis. However, personality changes caused by disease progression can be difficult to separate from changes that occur with normal aging....

Descripción completa

Detalles Bibliográficos
Autores principales:	Aschenbrenner, Andrew J., Petros, Jennifer, McDade, Eric, Wang, Guoqiao, Balota, David A., Benzinger, Tammie LS, Cruchaga, Carlos, Goate, Alison, Xiong, Chengjie, Perrin, Richard, Fagan, Anne M., Graff‐Radford, Neill, Ghetti, Bernardino, Levin, Johannes, Weidinger, Endy, Schofield, Peter, Gräber, Susanne, Lee, Jae‐Hong, Chhatwal, Jasmeer P., Morris, John C., Bateman, Randall, Hassenstab, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Cognitive & Behavioral Assessment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311802/ https://www.ncbi.nlm.nih.gov/pubmed/32587883 http://dx.doi.org/10.1002/dad2.12038

Ejemplares similares

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018)

Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2019)

Discovery and validation of autosomal dominant Alzheimer’s disease mutations
por: Hsu, Simon, et al.
Publicado: (2018)

Predicting sporadic Alzheimer’s disease progression via inherited Alzheimer’s disease-informed machine-learning
por: Franzmeier, Nicolai, et al.
Publicado: (2020)

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
por: Strain, Jeremy F., et al.
Publicado: (2022)

Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease
por: Vermunt, Lisa, et al.
Publicado: (2020)

First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease: the Dominantly Inherited Alzheimer’s Network Study
por: O'Connor, Antoinette, et al.
Publicado: (2023)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease
por: Hassenstab, Jason, et al.
Publicado: (2021)

Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease
por: Schultz, Stephanie A., et al.
Publicado: (2020)

Falls: a marker of preclinical Alzheimer disease: a cohort study protocol
por: Bollinger, Rebecca M, et al.
Publicado: (2021)

Neurological Manifestations of Autosomal Dominant Alzheimer’s Disease from the DIAN cohort and a meta-analysis
por: Tang, Mengxuan, et al.
Publicado: (2016)

Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease
por: Müller, Stephan, et al.
Publicado: (2017)

Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network
por: Karch, Celeste M., et al.
Publicado: (2018)

Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease
por: Chen, Hsiang-Han, et al.
Publicado: (2022)

Weakly activated core inflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer’s disease
por: Li, Fuhai, et al.
Publicado: (2021)

Current advances in digital cognitive assessment for preclinical Alzheimer's disease
por: Öhman, Fredrik, et al.
Publicado: (2021)

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)

Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease
por: Joseph-Mathurin, Nelly, et al.
Publicado: (2021)

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer disease: a longitudinal study
por: Gordon, Brian A., et al.
Publicado: (2018)

Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease
por: Gonneaud, Julie, et al.
Publicado: (2021)

Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer’s disease
por: Llibre-Guerra, Jorge J, et al.
Publicado: (2023)

Weakly activated core neuroinflammation pathways were identified as a central signaling mechanism contributing to the chronic neurodegeneration in Alzheimer’s disease
por: Li, Fuhai, et al.
Publicado: (2022)

Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer’s disease brains
por: Novotny, Brenna C., et al.
Publicado: (2023)

Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease
por: Aschenbrenner, Andrew J., et al.
Publicado: (2021)

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease
por: Johnson, Erik C. B., et al.
Publicado: (2023)

Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study
por: Millar, Peter R, et al.
Publicado: (2023)

Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials
por: Aschenbrenner, Andrew J., et al.
Publicado: (2022)

White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer’s disease
por: Lee, Seonjoo, et al.
Publicado: (2018)

Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease
por: Wang, Qing, et al.
Publicado: (2022)

Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies
por: Ringman, John M., et al.
Publicado: (2014)

Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2022)

Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease
por: Joseph-Mathurin, Nelly, et al.
Publicado: (2018)

Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia
por: Ying, Chunwei, et al.
Publicado: (2023)

Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease
por: Schultz, Stephanie A., et al.
Publicado: (2023)

Revolutionizing Alzheimer's disease and clinical trials through biomarkers
por: Mattsson, Niklas, et al.
Publicado: (2015)

Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)

Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease
por: Wang, Qing, et al.
Publicado: (2019)

Covariance-based vs. correlation-based functional connectivity dissociates healthy aging from Alzheimer disease
por: Strain, Jeremy F., et al.
Publicado: (2022)

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome
por: Henson, Rachel L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_aq2cre52j0eruv473jpg8vtn53